Together, this improved T-cell proliferation and the cytotoxic potential of CD8+ T-cells in the tumour, and allowed evofosfamide, in combination with CTLA-4/PD-1 blockade, to cure most animals bearing TRAMP-C2 tumours (82% overall survival) [154]. The gene discussed is CD8A; the disease is neoplasm.